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Abstract
Burkholderia pseudomallei is a Gram-negative environmental bacterium that causes melioidosis, a potentially life-
threatening infectious disease affecting mammals, including humans. Melioidosis symptoms are both protean and diverse,
ranging from mild, localized skin infections to more severe and often fatal presentations including pneumonia, septic shock
with multiple internal abscesses and occasionally neurological involvement. Several ubiquitous virulence determinants in B.
pseudomallei have already been discovered. However, the molecular basis for differential pathogenesis has, until now,
remained elusive. Using clinical data from 556 Australian melioidosis cases spanning more than 20 years, we identified a
Burkholderia mallei-like actin polymerization bimABm gene that is strongly associated with neurological disease. We also
report that a filamentous hemagglutinin gene, fhaB3, is associated with positive blood cultures but is negatively correlated
with localized skin lesions without sepsis. We show, for the first time, that variably present virulence factors play an
important role in the pathogenesis of melioidosis. Collectively, our study provides a framework for assessing other non-
ubiquitous bacterial virulence factors and their association with disease, such as candidate loci identified from large-scale
microbial genome-wide association studies.
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Introduction
Burkholderia pseudomallei and its equine-adapted clonal derivative
Burkholderia mallei (the causal agent of glanders) are formidable
pathogens. In 2012, B. pseudomallei and B. mallei were upgraded to
Tier 1 Select Agent status in the United States, a ranking reserved
for only those infectious agents that pose the greatest risk to human
and animal health and which also includes Bacillus anthracis
(anthrax) and Yersinia pestis (plague) [1]. Our knowledge of the
global distribution of B. pseudomallei is expanding as regions of
endemicity continue to be unveiled, with this bacterium now
considered endemic in tropical northern Australia, many countries
in Asia, selected locations in the Americas and Africa, and several
islands in the Indian and Pacific Ocean islands [2]. Northeast
Thailand and the tropical Top End of the Northern Territory in
Australia are hyperendemic for this bacterium, with melioidosis
being a major cause of community-acquired pneumonia and sepsis
in these regions [3,4].
The fulminating septicemic form of melioidosis has a mortality
rate up to 90%, and overall mortality in northeastern Thailand
remains at 40% despite over two decades of research and
improved therapy [4]. In contrast, the mortality rate of B.
pseudomallei infection in northern Australia is now comparatively
low at 10–15% [3]. In addition, up to 5% of Australian melioidosis
cases have a neurological presentation with an encephalomyelitis
syndrome that rarely occurs in Thailand or elsewhere in Southeast
Asia [3,5,6]. Despite the clear importance of B. pseudomallei and the
disease it causes, the role of genetic variation in the B. pseudomallei
genome and its association with disease severity has remained
elusive.
Several ubiquitous virulence factors in B. pseudomallei have
previously been identified, including the cytotoxin Burkholderia
lethal factor 1 [7], capsular polysaccharide I [8], the cluster I type
VI secretion system [9], and the Bsa type III secretion system
cluster 3 [10]. However, the wide spectrum of melioidosis
presentations has led to speculation that variably present virulence
factors may influence disease severity. To examine this potential,
we identified two variably present virulence candidates, deter-
mined their prevalence among 556 Australian B. pseudomallei
strains of clinical origin collected over a 24-year period, and
finally, compared their association with disease presentation and
severity.
Results and Discussion
The first variable virulence candidate we examined was
Burkholderia intracellular motility factor A (BimA), a putative type
V effector protein [11] required for actin-based motility. BimA
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subverts host actin dynamics, enabling bacterial movement
between eukaryotic cells and evasion of immune surveillance
[11,12]. All B. pseudomallei strains encode for BimA; however,
approximately 12% of northern Australian strains possess a bimA
variant that shares 95% homology with Burkholderia mallei (bimABm)
[13,14]. B. mallei is an equine-adapted clone of B. pseudomallei that
causes glanders, a highly infectious disease primarily of horses but
which is often fatal in humans if untreated [15]. BimABm shares
only 54% homology with BimABp, although both variants impart
actin polymerization capabilities [11]. The BimABp and BimABm
carboxy-terminal ends share homology with the Yersinia auto-
secreted adhesion YadA [16], a critical virulence factor in Y.
enterocolitica that enables host cell invasion while resisting immune
attack [17].
Using multivariate logistic regression models to control for all
potential confounders, we found a significant association between
bimABm and neurological melioidosis (p,0.001), with patients
infected by the bimABm variant being 14 times more likely to
present with neurological involvement compared with patients
infected with the bimABp variant (95% CI= 4.7–44.6). No
covariates were found to be associated with neurological disease,
indicating that bimABm was the only variable predictive of
neurological presentation. In contrast, patients infected with B.
pseudomallei possessing the bimABp variant were twice as likely to
develop pneumonia compared with those infected with the bimABm
variant (p=0.028; 95% CI= 1.1–3.5), although several covariates
existed for this presentation; specifically, being indigenous
Australian Aboriginal, having chronic lung or heart disease,
hazardous alcohol use, being older, not having a malignancy, and
no history of kava use. Pneumonia is the most common melioidosis
presentation in Australia, occurring in 51% of cases [3]; thus, the
identification of multiple covariates for pneumonia is not
unexpected. The bimABm variant has not yet been observed in
clinical and environmental isolates from Thailand or in other
endemic regions of Southeast Asia including Cambodia, Laos and
Vietnam [14], although the bimABm variant has been found in two
isolates originating from India [18]. Thus, the apparent absence of
the bimABm variant in Southeast Asia could explain the reduced
incidence of encephalomyelitis observed in this region.
Previous studies in a murine model have demonstrated that
intranasal delivery of B. pseudomallei or B. mallei can result in
invasive entry into the central nervous system, probably via the
olfactory nerve, enabling the bacteria to directly infect the brain
without hematogenous spread [19,20]. In addition, neurological
degeneration has been reported in a study on experimental
glanders in horses [21]. Based on these studies, the prevailing
hypothesis is that an intranasal route of infection substantially
increases the risk of bacterial migration to the brain. We
demonstrate that B. pseudomallei strains possessing the bimABm
variant have a substantially heightened ability to cause central
nervous system disease, possibly due to enhanced bacterial motility
along the olfactory and other nerve pathways [20]. Although it
remains unclear to what extent an inhalational/intranasal route of
infection contributes to neurological melioidosis in humans, our
findings suggest that inhalation or nasal aspiration of a bimABm
variant substantially increases the likelihood of developing a brain
infection compared with a bimABp variant.
The second variable virulence candidate we tested encodes for a
filamentous hemagglutinin (FhaB). B. pseudomallei contains one
ubiquitous FhaB (encoded by BPSS1727) [22] and three variably
present FhaB loci. Of the latter, B. pseudomallei strains can contain
one, two or all three fhaB genes [23]. These variably present genes
are located on genomic islands (GIs), and previous reports have
suggested a role in B. pseudomallei virulence [23,24]. Of note, the
variably present FhaB3 (encoded by BPSS2053 in B. pseudomallei
K96243) is an anti-macrophage factor [25] involved in host
epithelial cell attachment [24], the formation of multinucleated
giant cells and actin-associated membrane protrusions [26].
BPSS2053 shares 47% homology with Bordetella pertussis FhaB, an
adhesin that facilitates attachment to the host cell during infection,
the secretion of which is dependent upon FhaC [27]. Due to its
immunogenicity, FhaB from B. pertussis is as an essential
component of the acellular pertussis (whooping cough) vaccine
[28].
The majority (83%) of B. pseudomallei isolates examined in our
study possessed fhaB3. Using multivariate logistic regression
models to control for all potential confounders, we found that
patients harboring fhaB3-positive B. pseudomallei were twice as likely
to be blood culture-positive (p=0.028; 95% CI= 1.1–3.4),
although there was no significant association with septic shock
or mortality. Several covariates existed for blood culture-positivity;
namely, being indigenous Australian Aboriginal, being older,
having diabetes, immunosuppression or malignancy, and hazard-
ous alcohol use. In contrast, we observed a strong correlation
between fhaB3 absence and cutaneous melioidosis without sepsis,
with fhaB3-negative B. pseudomallei being four times more likely to
be the infecting organism in these patients (p=0.001; 95%
CI= 1.8–8.1). Cutaneous melioidosis without sepsis occurs as the
primary presentation in 13% of Australian cases [3], mostly in
those with no identified risk factors and commonly in children;
furthermore, fatalities have yet to be documented in this cohort
[29].
It is intriguing that fhaB3 has, to date, been found in 100% of
Thai B. pseudomallei strains [23] compared with only 83% of
Australian strains, and as such it is tempting to speculate that fhaB3
may contribute to increased mortality in Thai melioidosis patients.
However, our study did not find an association between fhaB3 and
mortality. In addition, the potential contribution of fhaB3 to
differential mortality rates between Thailand and Australia
requires evaluation in the context of differences in access to
diagnostic and therapeutic resources, and in particular, to state-of-
the-art critical care management of severe sepsis [30]. Although
further work is needed to identify other virulence determinants
associated with mortality, it is striking that B. pseudomallei strains
lacking fhaB3 are significantly less likely to cause severe disease.
Indeed, it is possible that fhaB3, in concert with another virulence
factor, contributes to adverse melioidosis outcomes.
In addition to the fhaB3 and bimA genes, we screened our isolate
collection for the Burkholderia thailandensis-like flagellum and
chemotaxis (BTFC) and the Yersinia-like fimbrial (YLF) gene
clusters, which are mutually exclusive in the B. pseudomallei genome
[31]. The BTFC and YLF gene clusters are putative virulence
determinants, with the YLF cluster previously shown to be over-
represented in clinical isolates [31]. Like fhaB3, the YLF cluster is
more common in Thailand than Australia and as expected, we
found that the majority of isolates in our study possessed the BTFC
cluster (79%). We performed BTFC/YLF analysis across 543
strains from our clinical collection with the same parameters used
for bimA and fhaB3 to assess correlation with disease presentation
and severity metrics. Interestingly, no statistically significant
correlations for clinical presentations or disease severity metrics
were identified for BTFC or YLF (Table S3). There was, however,
an overrepresentation of the YLF gene cluster in strains from
remote regions of Australia. The lack of correlation of any clinical
presentation or disease severity metric with BTFC/YLF in our
Australian isolates is itself significant as it highlights the
nonrandom nature of our bimA and fhaB3 findings.
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Associations between variable virulence factors and adverse
disease outcome are still poorly understood, although salient
examples have been documented in well-studied human patho-
gens, most notably nontyphoid Salmonella [32] and Shiga-toxin
producing Escherichia coli [33]. Our study has conclusively
identified, for the first time, variably present B. pseudomallei
virulence factors that are associated with specific melioidosis
presentations. The bimABm variant was shown to be highly
predictive of neurological melioidosis, and most likely explains
why this disease presentation is more frequently observed in
Australia than Thailand. Further, we have demonstrated that B.
pseudomallei strains lacking fhaB3 are significantly associated with
non-severe cutaneous disease compared with strains containing
fhaB3, a finding which potentially contributes to the lower
mortality rate of melioidosis in Australia. In contrast, strains
containing fhaB3 were associated with positive blood cultures, but
not septic shock or mortality, suggesting that additional virulence
factors remain to be identified. In contrast, we did not find any
association between BTFC/YLF and disease presentation or
disease severity. Collectively, our findings represent a fundamental
step towards understanding the molecular basis for variable disease
presentation caused by this high-threat biological agent, and
ongoing microbial genome-wide association studies are likely to
uncover additional virulence signatures.
Materials and Methods
Ethics Statement
Our study examined primary B. pseudomallei isolates obtained
from 556 melioidosis patients from the Darwin Prospective
Melioidosis Study, which commenced at Royal Darwin Hospital,
Northern Territory, Australia in October 1989. Ethics approval
for this study was obtained through the Human Research Ethics
Committee of the Northern Territory Department of Health and
Menzies School of Health Research, approval number HREC 02/
38 (Clinical and Epidemiological Features of Melioidosis) with
written informed consent obtained from patients. All patient data
were de-identified prior to analysis.
PCR Assay Design and PCR Conditions
The presence of fhaB3, bimABm, bimABp, BTFC and YLF among
the B. pseudomallei isolates was determined using real-time PCR.
For bimABm, 0.9 mM of each primer (AGCGCTTCGCGCATC-
TAC, CGCGTTAAACGCCGTACTTTC) (Invitrogen, Mul-
grave, VIC, Australia) and 0.25 mM TaqMan minor groove-
binding probe (6FAM-ATGCGCTCGCTATC) (Applied Biosys-
tems, Foster City, CA, USA) was used to generate a 104 bp
amplicon within this 579 bp gene (corresponding to
BURPS668_A2118 in B. pseudomallei MSHR668). Identical primer
(GGAAGCTTTGGCGTGCATAT, CCCATGCCTTCCTC-
GACTAAT) and probe (6FAM-ACGTCACTGCCAATC) con-
centrations were used to detect a unique 60 bp fragment within
the 1.5 kb bimABp locus (encoded by BPSS1492 in B. pseudomallei
K96243 [34]). For fhaB3 detection, 0.3 mM each primer
(GACGCGGCACGTCTGATC, CGCGGATAAAACTCG-
GATTG) and 0.2 mM probe (6FAM-AACCAGGTCAACAGCA)
was used to generate a conserved 58 bp product within the 9.3 kb
fhaB3 gene (BPSS2053 in K96243). For BTFC and YLF detection,
primers and probes were designed targeting lafU or BPSS0124
(corresponding to BTFC and YLF loci, respectively). BTFC and
YLF detection was multiplexed into a single assay containing
0.3 mM of each primer (TGTTTCGCAGCGAGGATGTC,
CCCACCGTCAAGCCGATT) and 0.2 mM of probe (6FAM-
CGTCCGACCGAGTGC) targeting BTFC and identical con-
centrations of primers (GTGCCTGCAACGCTAATCG,
CGCACTGATAGCCGGAATAGAG) and probe (VIC-ACTG-
GATTTACTCAGCGCAT) targeting YLF. Positive controls for
bimABp, bimABm, BTFC, YLF or fhaB3 were included on each PCR
plate to ensure accurate assay performance. All PCRs used
TaqMan Universal Mastermix (Applied Biosystems) and were
carried out to a final volume of 5 mL, in duplicate. PCR
instrumentation and conditions were as previously described [35].
Clinical and Epidemiological Features of Melioidosis
Cases
We categorized the 556 patients into six primary (and mutually
exclusive) diagnoses: pneumonia, genitourinary involvement,
blood culture positivity but no identifiable focus, localized skin
infection without sepsis, neurological melioidosis and internal soft
tissue abscess. Disease severity metrics were also included, where
relevant: blood culture-positive growth of B. pseudomallei, septic
shock, and mortality. Melioidosis risk factors were scored as either
present or absent for the following, as previously defined for the
Darwin Prospective Melioidosis Study [3]: chronic lung disease,
chronic renal disease, diabetes, hazardous alcohol use, heart
disease (defined as either rheumatic heart disease or congestive
cardiac failure), immunosuppression, kava use and malignancy.
Criteria for defining hazardous alcohol use, chronic lung disease,
chronic renal disease and septic shock have previously been
detailed [3]. Last, four epidemiological factors were included to
rule out potential confounding influences: gender, ethnicity (either
indigenous Australian Aboriginal or not), age, and probable
acquisition of infection locality. Locality was divided into three
regions: urban Darwin, rural Darwin, or elsewhere in Australia,
including the remote Top End of the Northern Territory.
Statistical Analysis
All statistical analyses were carried out using Stata version 13.0
(StataCorp LP, College Station, TX, USA). Bivariate analysis was
performed using the Pearson’s x2 test where expected frequencies
were .5 in all cells, or the two-sided Fisher’s exact test where
expected frequencies were ,5 in one cell (Tables S1 and S2). The
Wilcoxon rank-sum test was used to compare age of diagnosis with
bimA or fhaB3 status. To rule out confounding factors (e.g. age,
geographic location, or risk factors) associated with bimA or fhaB3
status and clinical outcome, multivariate logistic regression
analyses were performed using a stepwise backwards-elimination
procedure as previously described [3]. We used a threshold of
p = 0.1 for inclusion of covariates in the logistic regression model,
followed by a p=0.01 for primary associations and a p = 0.05 for
secondary associations.
Supporting Information
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